What is GRI Bio Financial Strength?
GRI Bio has the Financial Strength Rank of 7.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
GuruFocus does not calculate GRI Bio's interest coverage with the available data.
As of today, GRI Bio's Altman Z-Score is 0.00.
Competitive Comparison of GRI Bio's Financial Strength
For the Biotechnology subindustry, GRI Bio's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GRI Bio's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GRI Bio's Financial Strength distribution charts can be found below:
* The bar in red indicates where GRI Bio's Financial Strength falls into.
GRI Bio Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
GRI Bio's Interest Expense for the
months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the
months ended in Mar. 2024 was $-1.90 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.11 Mil.
GRI Bio's Interest Coverage for the quarter that ended in Mar. 2024 is
| GuruFocus does not calculate GRI Bio's interest coverage with the available data. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
GRI Bio's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
GRI Bio has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRI Bio (GRI Bio) Business Description
Traded in Other Exchanges
N/A
Address
2223 Avenida De La Playa, Suite 208, La Jolla, CA, USA, 92037
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis.
Executives
| David Leslie Szekeres |
director |
C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT, SUITE 210, SAN DIEGO CA 92121 |
| Roelof Rongen |
director |
C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921 |
| Camilla V Simpson |
director |
20 ELAINE AVE., MILL VALLEY CA 94941 |
| Albert Agro |
officer: Chief Medical Officer |
828 RICHMOND STREET WEST, TORONTO A6 M6J 1C9 |
| Walter Marc Hertz |
director, 10 percent owner, officer: Chief Executive Officer |
2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037 |
| Vipin Chaturvedi |
officer: Chief Scientific Officer |
2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037 |
| Meenu Chhabra |
director |
C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103 |
| Joseph E Payne |
director |
10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121 |
| Leanne M. Kelly |
officer: Chief Financial Officer |
C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH STREET, SUITE 300, PHILADELPHIA PA 19103 |
| Marella Thorell |
director |
1226 CHARTER LANE, AMBLER PA 19002 |
| Arcturus Therapeutics Holdings Inc. |
10 percent owner |
10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121 |
| Penny Toren |
officer: SVP, Regul Affairs & Prog Mgmt |
C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103 |
| Ofir Levi |
director |
C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103 |
| Richard Ammer |
director, 10 percent owner |
C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103 |
| Pharma Gmbh Salmon |
10 percent owner |
SANKT-JACOBS-STRASSE 90, CH-9002, BASEL V8 4052 |
GRI Bio (GRI Bio) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GRI has been successfully added to your